Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration-Approved Anticancer Drugs: A Call for Systematic Data Availability.
Publication
, Journal Article
Modi, ND; Swain, SM; Buyse, M; Kuderer, NM; Rowland, A; Rockhold, FW; Sorich, MJ; Hopkins, AM
Published in: J Clin Oncol
November 10, 2024
Unlocking the full potential of clinical trials through comprehensive CSR and IPD sharing can revolutionize cancer care, enhance safety evaluations, and reduce bias in systematic reviews. It is time for all stakeholders to embrace transparency and advance patient-centered outcomes.
Duke Scholars
Published In
J Clin Oncol
DOI
EISSN
1527-7755
Publication Date
November 10, 2024
Volume
42
Issue
32
Start / End Page
3773 / 3777
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Oncology & Carcinogenesis
- Neoplasms
- Humans
- Drug Approval
- Clinical Trials as Topic
- Antineoplastic Agents
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Modi, N. D., Swain, S. M., Buyse, M., Kuderer, N. M., Rowland, A., Rockhold, F. W., … Hopkins, A. M. (2024). Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration-Approved Anticancer Drugs: A Call for Systematic Data Availability. J Clin Oncol, 42(32), 3773–3777. https://doi.org/10.1200/JCO.24.00539
Modi, Natansh D., Sandra M. Swain, Marc Buyse, Nicole M. Kuderer, Andrew Rowland, Frank W. Rockhold, Michael J. Sorich, and Ashley M. Hopkins. “Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration-Approved Anticancer Drugs: A Call for Systematic Data Availability.” J Clin Oncol 42, no. 32 (November 10, 2024): 3773–77. https://doi.org/10.1200/JCO.24.00539.
Modi ND, Swain SM, Buyse M, Kuderer NM, Rowland A, Rockhold FW, et al. Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration-Approved Anticancer Drugs: A Call for Systematic Data Availability. J Clin Oncol. 2024 Nov 10;42(32):3773–7.
Modi, Natansh D., et al. “Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration-Approved Anticancer Drugs: A Call for Systematic Data Availability.” J Clin Oncol, vol. 42, no. 32, Nov. 2024, pp. 3773–77. Pubmed, doi:10.1200/JCO.24.00539.
Modi ND, Swain SM, Buyse M, Kuderer NM, Rowland A, Rockhold FW, Sorich MJ, Hopkins AM. Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration-Approved Anticancer Drugs: A Call for Systematic Data Availability. J Clin Oncol. 2024 Nov 10;42(32):3773–3777.
Published In
J Clin Oncol
DOI
EISSN
1527-7755
Publication Date
November 10, 2024
Volume
42
Issue
32
Start / End Page
3773 / 3777
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Oncology & Carcinogenesis
- Neoplasms
- Humans
- Drug Approval
- Clinical Trials as Topic
- Antineoplastic Agents
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis